Trial Profile
A Phase 3, Randomized, Double-Blind, Controlled, Multicenter, Clinical Study to Evaluate Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Influenza Vaccine in Comparison With an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine and an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine Containing the Alternate B Strain, in Adults Aged 65 Years and Above
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Influenza vaccine quadrivalent Seqirus (Primary) ; MF 59
- Indications Influenza A virus H1N1 subtype; Influenza A virus H3N2 subtype; Influenza B virus infections; Influenza virus infections
- Focus Pharmacodynamics
- Sponsors Seqirus
- 18 Oct 2019 Results assessing adjuvanted quadrivalent influenza vaccine induces a similar immune, reactogenicity and safety profile as the licensed adjuvanted trivalent influenza vaccine against homologous influenza vaccines were published in the Vaccine.
- 10 Jun 2018 Status changed from active, no longer recruiting to completed.
- 15 Nov 2017 Status changed from recruiting to active, no longer recruiting.